James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why Barrick Gold Corporation (USA) (ABX), Interactive Brokers Group, Inc. (IBKR) and Kellogg Company (K) Are 3 of Today’s Worst Stocks

Barrick Gold (ABX), Interactive Brokers Group (IBKR) and Kellogg (K) investors couldn't wait to hear Wednesday's closing bell ring.

10 Healthcare Innovations That Will Change the World

Lots of companies are developing impressive, novel drugs and biotechnologies, but these healthcare outfits are close to reshaping how we view and think of health.

BIIB Stock: What to Know About Biogen Inc Before Thursday Morning

Biogen (BIIB) hit a wall a year ago when its flagship drug's sales growth stalled. This is not the same company though.

Why Humana Inc (HUM), Netflix, Inc. (NFLX) and Vale SA (ADR) (VALE) Are 3 of Today’s Worst Stocks

Humana (HUM), Netflix (NFLX) and Vale (VALE) ended the day in far worse trouble than the overall market did.

YHOO Stock: Yahoo! Inc. Is Just Waiting It Out

For all intents and purposes, the once-iconic Yahoo (YHOO) and its shareholders are now just waiting on the inevitable.